Company intelligence / Profile preview

Guangzhou Jinan Biomedicine Research and Development Center

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

The company has published pre-clinical results on polydatin and resveratrol indicating regulatory effects on metabolic biomarkers and oxidative stress through modulation of the AMPK signaling pathway and related receptors in the liver.

Therapeutic areas: Metabolic DisordersGastroenterology
Modalities: Small molecule
Industry: Academic Hospital/University/Research

Partnerships

Jinan University (co-founder and scientific partner)Guangzhou municipal government (co-founder)GinkgoAI (quality control partnership)

Beyond the preview

Go deeper on Guangzhou Jinan Biomedicine Research and Development Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Jinan Biomedicine Research and Development Center.

Explore the full profile